ANDA 201404, held by Acs Dobfar Spa. Ampicillin Sodium.
As of Nov 16, 2026, ANDA 201404 (Ampicillin Sodium), held by Acs Dobfar Spa, was first approved by FDA on Dec 20, 2013, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory Tract Infections caused by S. pneumoniae, Staphylococcus aureus (penicillinase and non-penicillinase producing), H. influenzae and Group A beta-hemolytic streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 20, 2013 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ampicillin SodiumEQ 10GM BASE/VIAL · injectable;injection | Ampicillin Sodium | Rx |
| May 1, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Feb 15, 2018 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 15, 2018 | Supplement 2Labeling · Standard review | Approved | None posted |
| Dec 20, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters